Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update
March 10, 2022 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 10, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development...
Achieve Life Sciences Announces Participation in March Investor Conferences
March 08, 2022 08:00 ET
|
Achieve Life Sciences
SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global...
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study
March 01, 2022 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, March 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of...
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022
February 24, 2022 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and...
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
February 16, 2022 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the...
Quit Genius, the #1 Digital Clinic for Addiction, Names Hinge Health Co-Founder Gabriel Mecklenburg to Board of Directors
February 14, 2022 09:00 ET
|
Quit Genius Medical, P.C.
NEW YORK, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Quit Genius, the world’s first digital clinic for treating multiple substance addictions, announced today that it has named Gabriel Mecklenburg,...
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award
February 03, 2022 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Announces Participation in February Investor Conferences
February 02, 2022 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
January 25, 2022 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference
January 06, 2022 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of...